In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time. Unfortunately, more than 1000 patients will die from this form of blood cancer in any given year and therefore new treatment options such as XPOVIO® are needed.
Antengene Corporation Limited today announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO® (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone (XBd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy and (2) in combination with dexamethasone (Xd) for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).
XPOVIO® is the first and only SINE approved by the TGA that helps to restore the body’s own tumour suppressor pathways.
Professor Hang Quach, Haematologist at St Vincent’s Hospital, Melbourne, commented, “I was privileged to be one of the investigators in the BOSTON clinical study and have since co-authored on a few papers on the XBd regimen. This triplet regimen is no doubt in my mind amongst the most effective therapies for early relapse in the era of lenalidomide refractoriness. On subset analyses, this triplet regimen is effective irrespective of age, frail or non-frail patients and is effective in patients with low creatinine clearance. Importantly, XBd combination was particularly effective in patients with high-risk cytogenetics.
Professor Hang Quach further commented “I believe that the first three lines of therapy for MM are the most important in dictating a patient’s overall survival because the majority of patients with MM in the real-world setting will not live to see fourth line of treatment or beyond. Moreover, the greatest clinical benefit is gained when an effective treatment is used in early-line relapse. It is therefore important that the clinician be given enough choice in that “one to three prior line” space to allow the most optimal regimen to be used based on a patient’s clinical profile. The lack of sufficient choices for lenalidomide-refractory patients in early-line relapse of MM is an area of unmet need in Australia. The availability of XPOVIO®, bortezomib and dexamethasone as an option in this space will address this unmet need.”
“In Australia, one critical area of unmet need for patients with myeloma is the lack of effective therapies for patients who are triple-class refractory, that is refractory to a proteasome inhibitor, immunomodulatory drug and an anti-CD38 monoclonal antibody. The benefit of XPOVIO® is that it is an oral drug with a completely novel mechanism of action which makes it ideal for triple-class refractory patients. XPOVIO® can induce responses and prolong life in a clinically meaningful way”, said Professor Andrew Spencer, Haematologist, Alfred Hospital, Melbourne.
Hayley Beer, Interim Co-CEO of Myeloma Australia, said “It is very important to have another treatment option for people living with multiple myeloma, in both earlier and later lines of therapy. XPOVIO® is a new class of drug with a unique mode of action, so it means that patients can try a new combination without necessarily recycling a previously used class of drug.”
“This is a significant milestone for Antengene and for MM patients in Australia. We are very pleased to be launching XPOVIO® and bring to Australian physicians and patients a novel addition to their existing regimens for the treatment of R/R MM. As our first product to be registered in Australia, it also marks the evolution of Antengene in Australia into a biopharmaceutical organization with a commitment to continued development and commercialization of transformational medicines for cancer and other life-threatening diseases in Australia,” said Thomas Karalis, CVP Asia Pacific of Antengene.
“The series of approvals granted to XPOVIO® in China, South Korea, Singapore and now Australia in the past six months have indicated the drug’s enormous therapeutic potential. In Australia, there are around 2,400 diagnosed cases of MM every year, thus presenting an urgent unmet clinical need in the treatment of MM,” said Jay Mei, Antengene’s Founder, Chairman and CEO. “This approval by the TGA is practice-changing for patients in Australia who have long suffered from MM. We are committed to bringing innovative drugs and therapies to patients with cancer or other life-threatening disease in the Asia Pacific region and around the world. Now, our commercial team is well prepared to further extend patients’ access to this novel therapy, building upon our commercialization experience with XPOVIO® launches in China, Singapore and South Korea.”